Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Cumberland Pharmaceuticals Inc

CPIX

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.

Last trade $5.54
Day change +$0.33 (+6.33%)
Day range $5.23 – $6.30
Volume 62,222
Market cap $78M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$78.13M
Price / earnings
1.14×
Price / book
1.08×
Price / sales
3.11×
EV / sales
-0.1×
EV / EBITDA
0.29×

Profitability

Earnings per share
$4.59
Return on assets
60.47%
Return on equity
94.89%
Dividend yield
28.77%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.05×
Quick ratio
3.04×
Cash ratio
2.35×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$987.32K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CPIX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.16M$166.46K$9.13M$13.68M$171.82K$380.8K$11.71M$10.44M
Cost of revenue$1.06M$0$1.93M$2.24M$0$0$1.43M$1.98M
Gross profit$1.09M$166.46K$7.2M$11.44M$171.82K$380.8K$10.29M$8.46M
Selling, general and administrative$2.18M$2.55M$7.62M$10.25M$2.38M$2.66M$6.69M$7.55M
Research and development$841.16K$772.16K$1.46M$1.55M$646.47K$837.4K$1.3M$1.29M
Total operating expenses$3.03M$3.33M$10.33M$12.81M$3.03M$3.5M$9M$10.3M
Operating income-$1.94M-$3.16M-$3.13M-$1.37M-$2.86M-$3.12M$1.29M-$1.84M
Interest expense-$4.6K-$724-$85.84K-$112.94K-$29-$471-$163.8K-$223.26K
Income before taxes-$1.59M-$3.1M-$3.28M-$1.39M-$2.72M-$2.99M$1.25M-$1.96M
Income taxes$3.87K$3.87K$3.87K$23.25K$5.67K$5.67K$5.67K-$57K
Net income$77.78M-$4.27M-$3.29M-$1.43M-$1.95M-$735.21K$1.25M-$1.9M
Net income attributable to common shareholders$77.78M-$4.28M-$3.29M-$1.41M-$1.94M-$740.74K$1.26M-$1.9M
EBITDA-$1.91M-$4.37M-$1.85M-$329.31K-$2.83M-$4.07M$2.32M-$345.65K
Basic earnings per share$5.19-$0.29-$0.22-$0.10-$0.13-$0.05$0.08-$0.14
Diluted earnings per share$5.07-$0.29-$0.22-$0.10-$0.13-$0.05$0.08-$0.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

RedHill Biopharma Receives Nasdaq Staff Determination Notification

RedHill Biopharma received a Nasdaq Staff Determination letter indicating non-compliance with minimum stockholders' equity requirements. The company plans to appeal the determination and believes its recent transaction with Cumberland Pharmaceuticals has improved its equity position.

GlobeNewswire Inc.

Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances in Gene Therapy and Novel Drug Approvals | DelveInsight

The Duchenne muscular dystrophy market is experiencing steady growth driven by advancements in gene therapies, exon-skipping drugs, and emerging treatment options. Key players are expanding pipelines with novel therapies in late-stage clinical trials, with potential market transformation expected between 2025-2034.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Aug 3, 2026$1.50Jul 31, 2026special

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.